' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID


Gewähltes Keyword: lung cancer

Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy.
Falk, M; Willing, E; Schmidt, S; Schatz, S; Galster, M; Tiemann, M; Ficker, JH; Brueckl, WM;
Curr Oncol. 2023; 30(2):1692-1698
Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.
Brueckl, WM; Reck, M; Schäfer, H; Neben, K; Griesinger, F; Rawluk, J; Krüger, S; Kokowski, K; Ficker, JH; Möller, M; Schueler, A; Laack, E;
J Geriatr Oncol. 2022;
Originalarbeiten (Zeitschrift)
Intrathoracic migration of a breast implant seven years after thoracotomy. A case report
Damirov, F; Zimmermann, J; Ketscher, C; Hatz, R; Manapov, F; Lindner, M
INT J SURG CASE REP. 2022; 98: 107506
High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC.
Grambozov, B; Stana, M; Kaiser, B; Karner, J; Gerum, S; Ruznic, E; Zellinger, B; Moosbrugger, R; Studnicka, M; Fastner, G; Sedlmayer, F; Zehentmayr, F;
Cancers (Basel). 2022; 14(3):
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program.
Illini, O; Fabikan, H; Swalduz, A; Vikstrom, A; Krenbek, D; Schumacher, M; Dudnik, E; Studnicka, M; Ohman, R; Wurm, R; Wannesson, L; Peled, N; Kian, W; Bar, J; Daher, S; Addeo, A; Rotem, O; Pall, G; Zer, A; Saad, A; Cufer, T; Sorotsky, HG; Hashemi, SMS; Mohorcic, K; Stoff, R; Rovitsky, Y; Keren-Rosenberg, S; Winder, T; Weinlinger, C; Valipour, A; Hochmair, MJ
THER ADV MED ONCOL. 2022; 14: 17588359221103206
Originalarbeiten (Zeitschrift)
Disease-related blood-based differential methylation in cystic fibrosis and its representation in lung cancer revealed a regulatory locus in PKP3 in lung epithelial cells.
Schamschula, E; Lahnsteiner, A; Assenov, Y; Hagmann, W; Zaborsky, N; Wiederstein, M; Strobl, A; Stanke, F; Muley, T; Plass, C; Tummler, B; Risch, A
Epigenetics. 2022; 17(8):837-860
Originalarbeiten (Zeitschrift)
Carbon Monoxide Diffusing Capacity (DL
Stana, M; Grambozov, B; Gaisberger, C; Karner, J; Ruznic, E; Berchtold, J; Zellinger, B; Moosbrugger, R; Studnicka, M; Fastner, G; Sedlmayer, F; Zehentmayr, F;
Diagnostics (Basel). 2022; 12(5):
Originalarbeiten (Zeitschrift)
Locally advanced NSCLC: a plea for sparing the ipsilateral normal lung-prospective, clinical trial with DART-bid (dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily) by VMAT.
Wurstbauer, K; Kazil, M; Meinschad, M; Pinter, R; De Vries, C; Clemens, P; Kreuter, C; Hernler, T; Hitzl, W; Cerkl, P; Kunzler, T; De Vries, A
RADIAT ONCOL. 2022; 17(1): 120
Originalarbeiten (Zeitschrift)
A nomogram to predict the recurrence-free survival and analyze the utility of chemotherapy in stage IB non-small cell lung cancer
Zhang, ZY; Xie, SH; Cai, WJ; Yang, CC; Hong, ZN; Lin, YK; Zhu, JF; Lin, ZW; Christoph, DC; Bohnenberger, H; Kepka, L; Brueckl, WM; Van Houtte, P; Kang, MQ; Lin, JB
TRANSL LUNG CANCER R. 2022; 11(1): 75-+.
Originalarbeiten (Zeitschrift)
Afatinib as first-line treatment in patients with
Bruckl, WM; Reck, M; Griesinger, F; Schafer, H; Kortsik, C; Gaska, T; Rawluk, J; Kruger, S; Kokowski, K; Budweiser, S; Ficker, JH; Hoffmann, C; Schuler, A; Laack, E
THER ADV MED ONCOL. 2021; 13: 17588359211012361
Originalarbeiten (Zeitschrift)
Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC)
Brueckl, NF; Wirtz, RM; Reich, FPM; Veltrup, E; Zeitler, G; Meyer, C; Wuerflein, D; Ficker, JH; Eidt, S; Brueckl, WM
TRANSL LUNG CANCER R. 2021; 10(11): 4106-+.
Originalarbeiten (Zeitschrift)
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV
Brueckl, WM; Reck, M; Rittmeyer, A; Kollmeier, J; Wesseler, C; Wiest, GH; Christopoulos, P; Stenzinger, A; Tufman, A; Hoffknecht, P; Ulm, B; Reich, F; Ficker, JH; Laack, E
Originalarbeiten (Zeitschrift)
Is It Legitimate for Society to Intervene in the Way Citizens Live Their Lives When the Cost of Health Care Has to Be Borne by the General Public?-General Considerations and Special Implications During the Covid-19 Pandemic.
Edlinger, C; Klein, D; Lichtenauer, M;
Front Public Health. 2021; 9: 653923
Originalarbeiten (Zeitschrift)
Re-Irradiation for Locally Recurrent Lung Cancer: A Single Center Retrospective Analysis.
Grambozov, B; Nussdorfer, E; Kaiser, J; Gerum, S; Fastner, G; Stana, M; Gaisberger, C; Wass, R; Studnicka, M; Sedlmayer, F; Zehentmayr, F;
Curr Oncol. 2021; 28(3):1835-1846
Originalarbeiten (Zeitschrift)
Impact of reirradiation, chemotherapy, and immunotherapy on survival of patients with recurrent lung cancer: A single-center retrospective analysis.
Grambozov, B; Wass, R; Stana, M; Gerum, S; Karner, J; Fastner, G; Studnicka, M; Sedlmayer, F; Zehentmayr, F
THORAC CANCER. 2021; 12(8): 1162-1170.
Originalarbeiten (Zeitschrift)
Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the TOaSTT database.
Kroeze, SGC; Schaule, J; Fritz, C; Kaul, D; Blanck, O; Kahl, KH; Roeder, F; Siva, S; Verhoeff, JJC; Adebahr, S; Schymalla, MM; Glatzer, M; Szuecs, M; Geier, M; Skazikis, G; Sackerer, I; Lohaus, F; Eckert, F; Guckenberger, M;
Radiat Oncol. 2021; 16(1):4
Originalarbeiten (Zeitschrift)
Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort Study.
Lang, D; Brauner, A; Huemer, F; Rinnerthaler, G; Horner, A; Wass, R; Brehm, E; Kaiser, B; Greil, R; Lamprecht, B;
Cancers (Basel). 2021; 14(1):
Originalarbeiten (Zeitschrift)
2-[ 18 F]FDG PET/CT radiomics in lung cancer: An overview of the technical aspect and its emerging role in management of the disease
Manafi-Farid, R; Karamzade-Ziarati, N; Vali, R; Mottaghy, FM; Beheshti, M;
Methods. 2021; 188: 84-97.
Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors.
Moreno, V; Greil, R; Yachnin, J; Majem, M; Wermke, M; Arkenau, HT; Basque, JR; Nidamarthy, PK; Kapoor, S; Cui, XM; Giovannini, M
CLIN THER. 2021; 43(6): 1092-1111.
Originalarbeiten (Zeitschrift)
External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients.
Barth, DA; Brenner, C; Riedl, JM; Prinz, F; Klocker, EV; Schlick, K; Kornprat, P; Lackner, K; St?ger, H; Stotz, M; Gerger, A; Pichler, M
CANCER MED-US. 2020; 9(15): 5473-5479.
Originalarbeiten (Zeitschrift)
Organ-restricted vascular delivery of nanoparticles for lung cancer therapy.
Bölükbas, DA; Datz, S; Meyer-Schwickerath, C; Morrone, C; Doryab, A; Gößl, D; Vreka, M; Yang, L; Argyo, C; van Rijt, SH; Lindner, M; Eickelberg, O; Stoeger, T; Schmid, O; Lindstedt, S; Stathopoulos, GT; Bein, T; Wagner, DE; Meiners, S;
Adv Ther (Weinh). 2020; 3(7):
Originalarbeiten (Zeitschrift)
Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.
Brueckl, WM; Reck, M; Rittmeyer, A; Kollmeier, J; Wesseler, C; Wiest, GH; Christopoulos, P; Tufman, A; Hoffknecht, P; Ulm, B; Reich, F; Ficker, JH; Laack, E
CLIN MED INSIGHTS-ON. 2020; 14: 1179554920951358
Originalarbeiten (Zeitschrift)
Results of the Austrian National Lung Cancer Audit.
Burghuber, OC; Kirchbacher, K; Mohn-Staudner, A; Hochmair, M; Breyer, MK; Studnicka, M; Mueller, MR; Feurstein, P; Schrott, A; Lamprecht, B; Eckmayr, J; Renner, F; Bolitschek, J; Pohl, W; Schenk, P; Errhalt, P; Cerkl, P; Baumgartner, B; Kneussl, M; Hartl, S
CLIN MED INSIGHTS-ON. 2020; 14: 1179554920950548
Originalarbeiten (Zeitschrift)
Pulmonary function decreases moderately after accelerated high-dose irradiation for stage III non-small cell lung cancer.
Grambozov, B; Wolf, F; Kaiser, J; Wass, R; Fastner, G; Gaisberger, C; Rettenbacher, L; Studnicka, M; Pirich, C; Sedlmayer, F; Zehentmayr, F;
Thorac Cancer. 2020; 11(2):369-378
Originalarbeiten (Zeitschrift)
Quality of Life and Limitations in Daily Life of Stable COPD Outpatients in a Real-World Setting in Austria - Results from the CLARA Project.
Horner, A; Burghuber, OC; Hartl, S; Studnicka, M; Merkle, M; Olschewski, H; Kaiser, B; Wallner, EM; Lamprecht, B;
Int J Chron Obstruct Pulmon Dis. 2020; 15:1655-1663
Originalarbeiten (Zeitschrift)
Prediction of Postoperative Clinical Outcomes in Resected Stage I Non-Small Cell Lung Cancer Focusing on the Preoperative Glasgow Prognostic Score.
Lindenmann, J; Fink-Neuboeck, N; Taucher, V; Pichler, M; Posch, F; Brcic, L; Smolle, E; Koter, S; Smolle, J; Smolle-Juettner, FM;
Cancers (Basel). 2020; 12(1):
Originalarbeiten (Zeitschrift)
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Riedl, JM; Barth, DA; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoeger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Posch, F;
Cancers (Basel). 2020; 12(8):
Originalarbeiten (Zeitschrift)
The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis.
Tran, T; Šterclová, M; Mogulkoc, N; Lewandowska, K; Müller, V; Hájková, M; Kramer, MR; Jovanović, D; Tekavec-Trkanjec, J; Studnicka, M; Stoeva, N; Hejduk, K; Dušek, L; Suissa, S; Vašáková, M;
Respir Res. 2020; 21(1): 11
Originalarbeiten (Zeitschrift)
Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review.
Zehentmayr, F; Grambozov, B; Kaiser, J; Fastner, G; Sedlmayer, F;
Thorac Cancer. 2020; 11(6): 137-1385.
Tissue ACE phenotyping in lung cancer.
Danilov, SM; Metzger, R; Klieser, E; Sotlar, K; Trakht, IN; Garcia, JGN;
PLoS One. 2019; 14(12): e0226553
Originalarbeiten (Zeitschrift)
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.
Dietel, M; Savelov, N; Salanova, R; Micke, P; Bigras, G; Hida, T; Antunez, J; Skov, BG; Hutarew, G; Sua, LF; Akita, H; Chan, OSH; Piperdi, B; Burke, T; Khambata-Ford, S; Deitz, AC
LUNG CANCER. 2019; 134: 174-179.
Originalarbeiten (Zeitschrift)
Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study.
Folch, EE; Pritchett, MA; Nead, MA; Bowling, MR; Murgu, SD; Krimsky, WS; Murillo, BA; LeMense, GP; Minnich, DJ; Bansal, S; Ellis, BQ; Mahajan, AK; Gildea, TR; Bechara, RI; Sztejman, E; Flandes, J; Rickman, OB; Benzaquen, S; Hogarth, DK; Linden, PA; Wahidi, MM; Mattingley, JS; Hood, KL; Lin, HY; Wolvers, JJ; Khandhar, SJ; Anciano, C; Aragaki, A; Arenberg, D; Awais, O; Balestra, R; Bansal, S; Barisione, E; Bechara, R; Benzaquen, S; Bezzi, M; Bhadra, K; Bird, J; Blanco, A; Bowling, M; Cerfolio, R; Christensen, M; Cicenia, J; Courey, A; Doty, J; Eggleston, K; Ellis, B; Fernandez, I; Flandes, J; Folch, E; Furman, A; Gass, GD; Gildea, T; Gogineni, A; Grabcanovic, MF; Hinze, JD; Hogarth, DK; Karunakara, R; Kazakov, J; Khandhar, S; Khurana, S; Krimsky, W; Krishna, G; Krol, R; Kropfmuller, R; Lamprecht, B; Lau, K; Lee, A; LeMense, G; Linden, P; Lutz, P; Mahajan, A; Mahmood, K; Maldonado, F; Martinez, R; Mattingley, J; Minnich, D; Murgu, S; Murillo, B; Nason, K; Nead, M; Parks, C; Perret, K; Porsch, P; Pritchett, M; Rickman, O; Rosario, M; Salio, M; Sarkar, S; Seevaratnam, A; Sethi, S; Singh, J; Studnicka, M; Sztejman, E; Takubo, T; Teba, C; Towe, C; Trigiani, M; Vergnon, J; Viby, NE; Wahidi, M; Waller, E; Wei, B; Zanchi, D; Zgoda, M
J THORAC ONCOL. 2019; 14(3): 445-458.
Originalarbeiten (Zeitschrift)
Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT.
Hörner-Rieber, J; Bernhardt, D; Blanck, O; Duma, M; Eich, HT; Gerum, S; Gkika, E; Hass, P; Henkenberens, C; Herold, HU; Hildebrandt, G; Imhoff, D; Kahl, H; Janssen, S; Jurianz, K; Krempien, R; Lautenschläger, SF; Lohaus, F; Mueller, AC; Petersen, C; Sackerer, I; Scafa, D; Schrade, E; Uhlmann, L; Wittig, A; Guckenberger, M;
Clin Lung Cancer. 2019; 20(6):-e677.
Originalarbeiten (Zeitschrift)
Molecular imaging of bone metastases using tumor-targeted tracers.
Karamzade-Ziarati, N; Manafi-Farid, R; Ataeinia, B; Langsteger, W; Pirich, C; Mottaghy, FM; Beheshti, M;
Q J Nucl Med Mol Imaging. 2019; 63(2):136-149
Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
Lang, D; Huemer, F; Rinnerthaler, G; Horner, A; Wass, R; Brehm, E; Akbari, K; Granitz, M; Hutarew, G; Kaiser, B; Greil, R; Lamprecht, B;
Target Oncol. 2019; 14(6): 707-717.
Originalarbeiten (Zeitschrift)
Targeted therapy in lung cancer-ASCO 2019 update
Wass, RE; Lang, D; Lamprecht, B; Studnicka, M
Survival in early lung cancer patients treated with high dose radiotherapy is independent of pathological confirmation.
Zehentmayr, F; Sprenger, M; Rettenbacher, L; Wass, R; Porsch, P; Fastner, G; Pirich, C; Studnicka, M; Sedlmayer, F;
Thorac Cancer. 2019; 10(2):321-329
Originalarbeiten (Zeitschrift)
[Rebiopsy for Patients with Lung Cancer - Joint Opinion from both the Endoscopic and Thoracic Oncology Sections of the German Society of Pneumology (DGP)].
Brückl, WM; Ficker, JH; Tiemann, M; Schumann, C; Reinmuth, N; Heigener, D; Schütte, W; Eberhardt, R; Darwiche, K; Wagner, M;
Pneumologie. 2018; 72(9): 617-623.
Originalarbeiten (Zeitschrift)
Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
Brueckl, WM; Achenbach, HJ; Ficker, JH; Schuette, W;
BMC Cancer. 2018; 18(1): 333
Originalarbeiten (Zeitschrift)
Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer.
Huemer, F; Rinnerthaler, G; Westphal, T; Hackl, H; Hutarew, G; Gampenrieder, SP; Weiss, L; Greil, R;
Oncotarget. 2018; 9(23):-16520
Originalarbeiten (Zeitschrift)
Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature.
Leitinger, M; Varosanec, MV; Pikija, S; Wass, RE; Bandke, D; Weis, S; Studnicka, M; Grinzinger, S; McCoy, MR; Hauer, L; Sellner, J
FRONT IMMUNOL. 2018; 9: 108
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Burgstaller, S; Fuchs, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Bartsch, R; Petru, E; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R;
BMC Cancer. 2018; 18(1): 1074
Originalarbeiten (Zeitschrift)
The effect of density overrides on magnetic resonance-guided radiation therapy planning for lung cancer.
Schrenk, O; Spindeldreier, CK; Schmitt, D; Roeder, F; Bangert, M; Burigo, LN; Pfaffenberger, A;
Phys Imaging Radiat Oncol. 2018; 8:23-27
Originalarbeiten (Zeitschrift)
[Trends in incidence of lung cancer according to histological subtype among men and women in Germany : Analysis of cancer registry data with the application of multiple imputation techniques].
Twardella, D; Geiss, K; Radespiel-Tröger, M; Benner, A; Ficker, JH; Meyer, M;
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018; 61(1): 20-31.
Originalarbeiten (Zeitschrift)
Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
Brückl, W; Tufman, A; Huber, RM;
Expert Rev Anticancer Ther. 2017; 17(2): 143-155.
Originalarbeiten (Zeitschrift)
[Liquid Biopsy: Detection of Molecular Markers for Treatment Decisions in Lung Cancer].
Brückl, WM; Wirtz, RM; Bertsch, T; Ficker, JH; Jung, A;
Pneumologie. 2017; 71(3): 151-163.
Originalarbeiten (Zeitschrift)
Comparison of
Erber, R; Stöhr, R; Herlein, S; Giedl, C; Rieker, RJ; Fuchs, F; Ficker, JH; Hartmann, A; Veltrup, E; Wirtz, RM; Brueckl, WM;
Anticancer Res. 2017; 37(12):6771-6778
Originalarbeiten (Zeitschrift)
[Haemoptysis : Intensive care management of pulmonary hemorrhage].
Ficker, JH; Bruckl, WM; Suc, J; Geise, A
Internist (Berl). 2017; 58(3):218-225
Originalarbeiten (Zeitschrift)
The CD24 surface antigen in neural development and disease.
Gilliam, DT; Menon, V; Bretz, NP; Pruszak, J;
Neurobiol Dis. 2017; 99:133-144
[Chemotherapy in the Elderly with Non-Small Cell Lung Cancer: A Non-Interventional, Prospective, Multicentric Observational Study].
Heigener, DF; Hoeffken, G; Wuerflein, D; Feurer, M; Rittmeyer, A; Huber, RM; Pietsch, M; Ring, A; Deppermann, KM
DEUT MED WOCHENSCHR. 2017; 142(4): e21-e27.
Originalarbeiten (Zeitschrift)
[HELP - Hospital Elder Life Program - multimodal delirium prevention in elderly patients].
Singler, K; Thomas, C
INTERNIST. 2017; 58(2): 125-131.
Originalarbeiten (Zeitschrift)
DART-bid for loco-regionally advanced NSCLC
Wurstbauer, K; Zehentmayr, F; Deutschmann, H; Dagn, K; Exeli, AK; Kopp, P; Porsch, P; Maurer, B; Studnicka, M; Sedlmayer, F
STRAHLENTHER ONKOL. 2017; 193(4): 315-323.
Originalarbeiten (Zeitschrift)
Evaluation of the role of remission status in a heterogeneous limited disease small-cell lung cancer patient cohort treated with definitive chemoradiotherapy.
Manapov, F; Niyazi, M; Gerum, S; Roengvoraphoj, O; Eze, C; Li, M; Hildebrandt, G; Fietkau, R; Klautke, G; Belka, C;
BMC Cancer. 2016; 16:216
Originalarbeiten (Zeitschrift)
Diagnostic performance of [18F] FDG PET-CT compared to bone scintigraphy for the detection of bone metastases in lung cancer patients.
Rodrigues, M; Stark, H; Rendl, G; Rettenbacher, L; Datz, L; Studnicka, M; Pirich, C;
Q J Nucl Med Mol Imaging. 2016; 60(1): 62-68.
Originalarbeiten (Zeitschrift)
Genetic changes of non-small cell lung cancer under neoadjuvant therapy.
Warth, A; Endris, V; Stenzinger, A; Penzel, R; Harms, A; Duell, T; Abdollahi, A; Lindner, M; Schirmacher, P; Muley, T; Dienemann, H; Fink, L; Morresi-Hauf, A; Pfarr, N; Weichert, W;
Oncotarget. 2016; 7(20):29761-29769
Originalarbeiten (Zeitschrift)
SNAI2/SLUG and estrogen receptor mRNA expression are inversely correlated and prognostic of patient outcome in metastatic non-small cell lung cancer.
Atmaca, A; Wirtz, RW; Werner, D; Steinmetz, K; Claas, S; Brueckl, WM; Jäger, E; Al-Batran, SE;
BMC Cancer. 2015; 15: 300
Originalarbeiten (Zeitschrift)
Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases.
Berghoff, AS; Ilhan-Mutlu, A; Dinhof, C; Magerle, M; Hackl, M; Widhalm, G; Hainfellner, JA; Dieckmann, K; Pichler, J; Hutterer, M; Melchardt, T; Bartsch, R; Zielinski, CC; Birner, P; Preusser, M;
Neuropathol Appl Neurobiol. 2015; 41(2):e41-e55
Originalarbeiten (Zeitschrift)
[Estrogen Receptors and their Impact for Prognosis and Therapy of Lung Cancer - New Insights to an Underestimated Mechanism].
Brückl, WM; Al-Batran, SE; Ficker, JH; Wirtz, RM; Atmaca, A;
Pneumologie. 2015; 69(6): 35-60.
Originalarbeiten (Zeitschrift)
Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series.
Dogan Onugoren, M; Deuretzbacher, D; Haensch, CA; Hagedorn, HJ; Halve, S; Isenmann, S; Kramme, C; Lohner, H; Melzer, N; Monotti, R; Presslauer, S; Schäbitz, WR; Steffanoni, S; Stoeck, K; Strittmatter, M; Stögbauer, F; Trinka, E; von Oertzen, TJ; Wiendl, H; Woermann, FG; Bien, CG;
J Neurol Neurosurg Psychiatry. 2015; 86(9): 965-972.
Originalarbeiten (Zeitschrift)
Comprehensive genomic profiles of small cell lung cancer.
George, J; Lim, JS; Jang, SJ; Cun, Y; Ozretić, L; Kong, G; Leenders, F; Lu, X; Fernández-Cuesta, L; Bosco, G; Müller, C; Dahmen, I; Jahchan, NS; Park, KS; Yang, D; Karnezis, AN; Vaka, D; Torres, A; Wang, MS; Korbel, JO; Menon, R; Chun, SM; Kim, D; Wilkerson, M; Hayes, N; Engelmann, D; Pützer, B; Bos, M; Michels, S; Vlasic, I; Seidel, D; Pinther, B; Schaub, P; Becker, C; Altmüller, J; Yokota, J; Kohno, T; Iwakawa, R; Tsuta, K; Noguchi, M; Muley, T; Hoffmann, H; Schnabel, PA; Petersen, I; Chen, Y; Soltermann, A; Tischler, V; Choi, CM; Kim, YH; Massion, PP; Zou, Y; Jovanovic, D; Kontic, M; Wright, GM; Russell, PA; Solomon, B; Koch, I; Lindner, M; Muscarella, LA; la Torre, A; Field, JK; Jakopovic, M; Knezevic, J; Castaños-Vélez, E; Roz, L; Pastorino, U; Brustugun, OT; Lund-Iversen, M; Thunnissen, E; Köhler, J; Schuler, M; Botling, J; Sandelin, M; Sanchez-Cespedes, M; Salvesen, HB; Achter, V; Lang, U; Bogus, M; Schneider, PM; Zander, T; Ansén, S; Hallek, M; Wolf, J; Vingron, M; Yatabe, Y; Travis, WD; Nürnberg, P; Reinhardt, C; Perner, S; Heukamp, L; Büttner, R; Haas, SA; Brambilla, E; Peifer, M; Sage, J; Thomas, RK;
Nature. 2015; 524(7563):47-53
Originalarbeiten (Zeitschrift)
Blood-sampling collection prior to surgery may have a significant influence upon biomarker concentrations measured.
Kahn, N; Riedlinger, J; Roeßler, M; Rabe, C; Lindner, M; Koch, I; Schott-Hildebrand, S; Herth, FJ; Schneider, MA; Meister, M; Muley, TR;
Clin Proteomics. 2015; 12(1):19
Originalarbeiten (Zeitschrift)
Endobronchial closure of bronchopleural fistula using Amplatzer device.
Klotz, LV; Gesierich, W; Schott-Hildebrand, S; Hatz, RA; Lindner, M;
J Thorac Dis. 2015; 7(8):147-182
Originalarbeiten (Zeitschrift)
Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry.
Kocher, F; Hilbe, W; Seeber, A; Pircher, A; Schmid, T; Greil, R; Auberger, J; Nevinny-Stickel, M; Sterlacci, W; Tzankov, A; Jamnig, H; Kohler, K; Zabernigg, A; Frötscher, J; Oberaigner, W; Fiegl, M;
Lung Cancer. 2015; 87(2):193-200
Originalarbeiten (Zeitschrift)
The L-type calcium channel Cav1.3 is required for proper hippocampal neurogenesis and cognitive functions.
Marschallinger, J; Sah, A; Schmuckermair, C; Unger, M; Rotheneichner, P; Kharitonova, M; Waclawiczek, A; Gerner, P; Jaksch-Bogensperger, H; Berger, S; Striessnig, J; Singewald, N; Couillard-Despres, S; Aigner, L;
Cell Calcium. 2015; 58(6): 606-616.
Originalarbeiten (Zeitschrift)
First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer.
Mikes, RE; Jordan, F; Hutarew, G; Studnicka, M;
Lung Cancer. 2015; 90(3): 614-616.
Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.
Petru, E; Singer, CF; Polterauer, S; Galid, A; Schauer, C; Klocker, J; Seifert, M; Reinthaller, A; Benedicic, C; Hubalek, M; Hefler, L; Marth, C; Scholl-Firon, T; Bogner, G; Zeimet, AG
Wien Med Wochenschr. 2015; 165(19-20):387-394
A randomized phase II study of radiation induced immune boost in operable non-small cell lung cancer (RadImmune trial).
Safi, S; Beckhove, P; Warth, A; Benner, A; Roeder, F; Rieken, S; Debus, J; Dienemann, H; Hoffmann, H; Huber, PE;
BMC Cancer. 2015; 15:988
Originalarbeiten (Zeitschrift)
Protease-mediated release of chemotherapeutics from mesoporous silica nanoparticles to ex vivo human and mouse lung tumors.
van Rijt, SH; Bölükbas, DA; Argyo, C; Datz, S; Lindner, M; Eickelberg, O; Königshoff, M; Bein, T; Meiners, S;
ACS Nano. 2015; 9(3):2377-2389
Originalarbeiten (Zeitschrift)
Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
Zehentmayr, F; Söhn, M; Exeli, AK; Wurstbauer, K; Tröller, A; Deutschmann, H; Fastner, G; Fussl, C; Steininger, P; Kranzinger, M; Belka, C; Studnicka, M; Sedlmayer, F;
Radiat Oncol. 2015; 10(1): 121
Originalarbeiten (Zeitschrift)
DART-bid: dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily : High local control in early stage (I/II) non-small-cell lung cancer.
Zehentmayr, F; Wurstbauer, K; Deutschmann, H; Fussl, C; Kopp, P; Dagn, K; Fastner, G; Porsch, P; Studnicka, M; Sedlmayer, F;
Strahlenther Onkol. 2015; 191(3): 256-263.
Originalarbeiten (Zeitschrift)
The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer.
Atmaca, A; Al-Batran, SE; Wirtz, RM; Werner, D; Zirlik, S; Wiest, G; Eschbach, C; Claas, S; Hartmann, A; Ficker, JH; Jäger, E; Brueckl, WM;
Int J Cancer. 2014; 134(10): 2314-2321.
Originalarbeiten (Zeitschrift)
Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases.
Berghoff, AS; Ilhan-Mutlu, A; Wöhrer, A; Hackl, M; Widhalm, G; Hainfellner, JA; Dieckmann, K; Melchardt, T; Dome, B; Heinzl, H; Birner, P; Preusser, M;
Strahlenther Onkol. 2014; 190(7):676-685
Originalarbeiten (Zeitschrift)
αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer.
Berghoff, AS; Kovanda, AK; Melchardt, T; Bartsch, R; Hainfellner, JA; Sipos, B; Schittenhelm, J; Zielinski, CC; Widhalm, G; Dieckmann, K; Weller, M; Goodman, SL; Birner, P; Preusser, M;
Clin Exp Metastasis. 2014; 31(7):841-851
Originalarbeiten (Zeitschrift)
Survival of patients with small cell lung cancer undergoing lung resection in England, 1998-2009.
Burney, P; Jithoo, A; Kato, B; Janson, C; Mannino, D; Nizankowska-Mogilnicka, E; Studnicka, M; Tan, W; Bateman, E; Kocabas, A; Vollmer, WM; Gislason, T; Marks, G; Koul, PA; Harrabi, I; Gnatiuc, L; Buist, S
Thorax. 2014; 69(3):269-273
Originalarbeiten (Zeitschrift)
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Butts, C; Socinski, MA; Mitchell, PL; Thatcher, N; Havel, L; Krzakowski, M; Nawrocki, S; Ciuleanu, TE; Bosquée, L; Trigo, JM; Spira, A; Tremblay, L; Nyman, J; Ramlau, R; Wickart-Johansson, G; Ellis, P; Gladkov, O; Pereira, JR; Eberhardt, WE; Helwig, C; Schröder, A; Shepherd, FA;
Lancet Oncol. 2014; 15(1): 59-68.
Originalarbeiten (Zeitschrift)
Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH.
Hutarew, G; Hauser-Kronberger, C; Strasser, F; Llenos, IC; Dietze, O
Histopathology. 2014; 65(3):398-407
Originalarbeiten (Zeitschrift)
Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
Kocher, F; Pircher, A; Mohn-Staudner, A; Romeder, F; Duller, W; Steinmaurer, M; Eckmayr, J; Schmid, T; Hilbe, W; Fiegl, M; Greil, R
LUNG CANCER. 2014; 85(3): 395-400.
Originalarbeiten (Zeitschrift)
Suitability of markerless EPID tracking for tumor position verification in gated radiotherapy.
Serpa, M; Baier, K; Cremers, F; Guckenberger, M; Meyer, J;
Med Phys. 2014; 41(3): 031702
Originalarbeiten (Zeitschrift)
Gli1 mediates lung cancer cell proliferation and Sonic Hedgehog-dependent mesenchymal cell activation.
Bermudez, O; Hennen, E; Koch, I; Lindner, M; Eickelberg, O;
PLoS One. 2013; 8(5):e63226
Originalarbeiten (Zeitschrift)
Prognostic and predictive value of estrogen receptor 1 expression in completely resected non-small cell lung cancer.
Brueckl, WM; Al-Batran, SE; Ficker, JH; Claas, S; Atmaca, A; Hartmann, A; Rieker, RJ; Wirtz, RM;
Int J Cancer. 2013; 133(8):1825-1831
Originalarbeiten (Zeitschrift)
EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice.
Gahr, S; Stoehr, R; Geissinger, E; Ficker, JH; Brueckl, WM; Gschwendtner, A; Gattenloehner, S; Fuchs, FS; Schulz, C; Rieker, RJ; Hartmann, A; Ruemmele, P; Dietmaier, W;
Br J Cancer. 2013; 109(7): 1821-1828.
Originalarbeiten (Zeitschrift)
Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells.
Kobold, S; Völk, S; Clauditz, T; Küpper, NJ; Minner, S; Tufman, A; Düwell, P; Lindner, M; Koch, I; Heidegger, S; Rothenfuer, S; Schnurr, M; Huber, RM; Wilczak, W; Endres, S;
J Thorac Oncol. 2013; 8(8):103-142
Originalarbeiten (Zeitschrift)
Immunotargeting of the pulmonary endothelium via angiotensin-converting-enzyme in isolated ventilated and perfused human lung.
Nowak, K; Kölbel, HC; Metzger, RP; Hanusch, C; Frohnmeyer, M; Hohenberger, P; Danilov, SM;
Adv Exp Med Biol. 2013; 756:203-212
Originalarbeiten (Zeitschrift)
Docetaxel in the treatment of non-small cell lung cancer (NSCLC) -- an observational study focusing on symptom improvement.
Pircher, A; Wasle, IK; Mian, M; Gamerith, G; Ulsperger, E; Studnicka, M; Mohn-Staudner, A; Hilbe, W; Fiegl, M
ANTICANCER RES. 2013; 33(9): 3831-3836.
Originalarbeiten (Zeitschrift)
Low dose CT screening for lung cancer: a statement of the Austrian Society of Radiology and the Austrian Society of Pneumology
Prosch, H; Studnicka, M; Eisenhuber, E; Olschewski, H; Stiefsohn, E; Hartl, S; Herold, C; Burghuber, O; Mostbeck, G
WIEN KLIN WOCHENSCHR. 2013; 125(11-12): 339-345.
Originalarbeiten (Zeitschrift)
Pulmonary infections imitating lung cancer: clinical presentation and therapeutical approach.
Schweigert, M; Dubecz, A; Beron, M; Ofner, D; Stein, HJ;
Ir J Med Sci. 2013; 182(1):73-80
Originalarbeiten (Zeitschrift)
A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka, EA; Levidou, G; Saetta, AA; Chatziandreou, I; Tomos, P; Thalassinos, N; Anastasiou, N; Spartalis, E; Kavantzas, N; Patsouris, E; Korkolopoulou, P;
Oncol Rep. 2013; 30(2):623-636
Originalarbeiten (Zeitschrift)
[Employing tyrosine kinase inhibitors in the first line treatment of EGFR-positive metastatic NSCLC - state of the art and recent developments].
Wiewrodt, R; Serke, M; Grohé, C; Brückl, W;
Pneumologie. 2013; 67(9): 494-501.
DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)-a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume
Wurstbauer, K; Deutschmann, H; Dagn, K; Kopp, P; Zehentmayr, F; Lamprecht, B; Porsch, P; Wegleitner, B; Studnicka, M; Sedlmayer, F
RADIAT ONCOL. 2013; 8:
Originalarbeiten (Zeitschrift)
A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis.
Campa, D; Müller, P; Edler, L; Knoefel, L; Barale, R; Heussel, CP; Thomas, M; Canzian, F; Risch, A;
Int J Cancer. 2012; 131(12): 2920-2928.
Originalarbeiten (Zeitschrift)
The impact of PET and PET/CT on treatment planning and prognosis of patients with NSCLC treated with radiation therapy.
Nawara, C; Rendl, G; Wurstbauer, K; Lackner, B; Rettenbacher, L; Datz, L; Studnicka, M; Sedlmayer, F; Pirich, C;
Q J Nucl Med Mol Imaging. 2012; 56(2): 19-201.
Originalarbeiten (Zeitschrift)
Tissue-Sparing Application of the Newly Proposed IASLC/ATS/ERS Classification of Adenocarcinoma of the Lung Shows Practical Diagnostic and Prognostic Impact
Sterlacci, W; Savic, S; Schmid, T; Oberaigner, W; Auberger, J; Fiegl, M; Tzankov, A
AM J CLIN PATHOL. 2012; 137(6): 946-956.
Originalarbeiten (Zeitschrift)
Immunosuppression and lung cancer of donor origin after bilateral lung transplantation.
von Boehmer, L; Draenert, A; Jungraithmayr, W; Inci, I; Niklaus, S; Boehler, A; Hofer, M; Stahel, R; Soltermann, A; van den Broek, M; Weder, W; Knuth, A;
Lung Cancer. 2012; 76(1):118-122
Originalarbeiten (Zeitschrift)
Polymorphisms in the apoptotic pathway gene BCL-2 and survival in small cell lung cancer.
Knoefel, LF; Werle-Schneider, G; Dally, H; Müller, PJ; Edler, L; Bartsch, H; Tuengerthal, S; Heussel, CP; Reinmuth, N; Thomas, M; Risch, A;
J Thorac Oncol. 2011; 6(1): 183-189.
Originalarbeiten (Zeitschrift)
[Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer].
Popper, H; Wrba, F; Gruber-Mösenbacher, U; Hulla, W; Pirker, R; Hilbe, W; Studnicka, M; Mohn-Staudner, A; Ploner, F;
Wien Klin Wochenschr. 2011; 123(9-10): 316-321.
Originalarbeiten (Zeitschrift)
[Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?].
Brückl, WM; Wiest, GH; Ficker, JH;
Pneumologie. 2010; 64(12): 727-735.
Atrial resection for lung cancer: morbidity, mortality, and long-term follow-up.
Kuehnl, A; Lindner, M; Hornung, HM; Winter, H; Jauch, KW; Hatz, RA; Graeb, C;
World J Surg. 2010; 34(9):2233-2239
Originalarbeiten (Zeitschrift)
Correlation of patient-related factors and dose-volume histogram parameters with the onset of radiation pneumonitis in patients with small cell lung cancer.
Roeder, F; Friedrich, J; Timke, C; Kappes, J; Huber, P; Krempien, R; Debus, J; Bischof, M;
Strahlenther Onkol. 2010; 186(3):149-156
Originalarbeiten (Zeitschrift)
Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients.
Sterlacci, W; Fiegl, M; Hilbe, W; Jamnig, H; Oberaigner, W; Schmid, T; Augustin, F; Auberger, J; Obermann, EC; Tzankov, A;
J Thorac Oncol. 2010; 5(9): 1325-1336.
Originalarbeiten (Zeitschrift)
Concordance between epidermal growth factor receptor status in primary non-small-cell lung cancer and metastases: a post-mortem study
Watzka, SB; Rauscher-Potsch, I; Nierlich, P; Setinek, U; Kostler, WJ; Potschger, U; Muller, MR; Attems, J
EUR J CARDIO-THORAC. 2010; 38(1): 34-37.
Originalarbeiten (Zeitschrift)
Nonresected non-small-cell lung cancer in Stages I through IIIB: accelerated, twice-daily, high-dose radiotherapy--a prospective Phase I/II trial with long-term follow-up.
Wurstbauer, K; Deutschmann, H; Kopp, P; Kranzinger, M; Merz, F; Nairz, O; Studnicka, M; Sedlmayer, F;
INT J RADIAT ONCOL. 2010; 77(5): 134-151.
Originalarbeiten (Zeitschrift)
Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses ≥ 80 Gy in standard fractionation.
Wurstbauer, K; Weise, H; Deutschmann, H; Kopp, P; Merz, F; Studnicka, M; Nairz, O; Sedlmayer, F;
STRAHLENTHER ONKOL. 2010; 186(10): 551-557.
Originalarbeiten (Zeitschrift)
Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer.
Pfeiffer, M; Hartmann, TN; Leick, M; Catusse, J; Schmitt-Graeff, A; Burger, M;
BRIT J CANCER. 2009; 100(12): 1949-1956.
Originalarbeiten (Zeitschrift)
Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases.
Sterlacci, W; Fiegl, M; Hilbe, W; Auberger, J; Mikuz, G; Tzankov, A;
Virchows Arch. 2009; 455(2): 125-132.
Originalarbeiten (Zeitschrift)
Target splitting in radiation therapy for lung cancer: further developments and exemplary treatment plans.
Wurstbauer, K; Deutschmann, H; Kopp, P; Merz, F; Scholler, H; Sedlmayer, F
Radiat Oncol. 2009; 4:30
Originalarbeiten (Zeitschrift)
Amphotericin B lozengers: prophylaxis for esophagitis in thoracic radiotherapy: a prospective study.
Wurstbauer, K; Merz, F; Sedlmayer, F;
STRAHLENTHER ONKOL. 2009; 185(8): 512-516.
Originalarbeiten (Zeitschrift)
[Drug therapy for small-cell lung cancer (SCLC)--new molecular strategies for therapy].
Brückl, WM; Lampert, S; Zirlik, S; Hahn, EG; Wiest, GH;
Pneumologie. 2008; 62(1):23-30
Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC).
Brueckl, WM; Schoeberl, A; Wirtz, RM; Murray, S; Hahn, EG; Wiest, GH;
J Thorac Oncol. 2008; 3(3): 314-316.
Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.
Fischer, H; Taylor, N; Allerstorfer, S; Grusch, M; Sonvilla, G; Holzmann, K; Setinek, U; Elbling, L; Cantonati, H; Grasl-Kraupp, B; Gauglhofer, C; Marian, B; Micksche, M; Berger, W;
MOL CANCER THER. 2008; 7(10): 3408-3419.
Originalarbeiten (Zeitschrift)
Significance of local therapies in the multimodality context for small cell lung cancer
Huber, RM; Lindner, M; Hatz, R; Flentje, M
ONKOLOGE. 2008; 14(8): 792-+.
Originalarbeiten (Zeitschrift)
Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9.
Sienel, W; Polzer, B; Elshawi, K; Lindner, M; Morresi-Hauf, A; Vay, C; Eder, F; Passlick, B; Klein, CA;
Mod Pathol. 2008; 21(9):1130-1138
Originalarbeiten (Zeitschrift)
Predictive and prognostic factors in small cell lung carcinoma (SCLC)--analysis from routine clinical practice.
Brueckl, WM; Herbst, L; Lechler, A; Fuchs, F; Schoeberl, A; Zirlik, S; Klein, P; Brunner, TB; Papadopoulos, T; Hohenberger, W; Hahn, EG; Wiest, GH;
ANTICANCER RES. 2007; 26(6C): 4825-4832.
Originalarbeiten (Zeitschrift)
[Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms].
Hilbe, W; Aigner, K; Dittrich, C; Eckmayr, J; Fiegl, M; Flicker, M; Forstner, B; Greil, R; Jamnig, H; Krajnik, G; Lang, A; Mohn-Staudner, A; Schinko, H; Studnicka, M; Pirker, R; Ploner, F; Rothmund, J; Schiller, L; Zabernigg, A; Zöchbauer-Müller, S;
Wien Klin Wochenschr. 2007; 119(7-8):259-266
Alterations of tumor and normal tissue of human lung cancer resection specimens after isolation perfusion.
Nowak, K; Hanusch, C; Kölbel, HC; Schwarzbach, M; Post, S; Beck, G; Gebhard, MM; Metzger, R; Hohenberger, P;
J Physiol Pharmacol. 2007; 58 Suppl 5(Pt 2):50-11
Originalarbeiten (Zeitschrift)
Lung cancer detection by proton transfer reaction mass-spectrometric analysis of human breath gas
Wehinger, A; Schmid, A; Mechtcheriakov, S; Ledochowski, M; Grabmer, C; Gastl, GA; Amann, A
INT J MASS SPECTROM. 2007; 265(1): 49-59.
Originalarbeiten (Zeitschrift)
NSCLC: primary tumor size--radiation dose-related accelerated, twice daily radiotherapy by target splitting, preceded by 2 cycles of chemotherapy--first results of a prospective study.
Wurstbauer, K; Deutschmann, H; Kopp, P; Kranzinger, M; Merz, F; Nairz, O; Studnicka, M; Sedlmayer, F;
STRAHLENTHER ONKOL. 2007; 183 Spec No 2: 38-40.
Originalarbeiten (Zeitschrift)
Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
Auberger, J; Loeffler-Ragg, J; Wurzer, W; Hilbe, W;
Curr Cancer Drug Targets. 2006; 6(4): 271-294.
Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer.
Grunwald, C; Koslowski, M; Arsiray, T; Dhaene, K; Praet, M; Victor, A; Morresi-Hauf, A; Lindner, M; Passlick, B; Lehr, HA; Schäfer, SC; Seitz, G; Huber, C; Sahin, U; Türeci, O;
Int J Cancer. 2006; 118(10):2522-2528
Originalarbeiten (Zeitschrift)
High rate of molecular alteration in histologically tumour-free bronchial epithelium of NSCLC patients detected by multicolour fluorescence in situ hybridisation.
Hilbe, W; Auberger, J; Dirnhofer, S; Schmid, T; Erdel, M; Duba, HC;
Oncol Rep. 2006; 15(5): 1233-1240.
Originalarbeiten (Zeitschrift)
Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.
Hohla, F; Schally, AV; Szepeshazi, K; Varga, JL; Buchholz, S; Köster, F; Heinrich, E; Halmos, G; Rick, FG; Kannadka, C; Datz, C; Kanashiro, CA;
P NATL ACAD SCI USA. 2006; 103(39): 14513-14518.
Originalarbeiten (Zeitschrift)
CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.
Hartmann, TN; Burger, JA; Glodek, A; Fujii, N; Burger, M;
Oncogene. 2005; 24(27):4462-4471
Originalarbeiten (Zeitschrift)
Radiotherapy planning for lung cancer: slow CTs allow the drawing of tighter margins.
Wurstbauer, K; Deutschmann, H; Kopp, P; Sedlmayer, F;
Radiother Oncol. 2005; 75(2):165-170
Originalarbeiten (Zeitschrift)
The role of adhesion molecules and chemokine receptor CXCR4 (CD184) in small cell lung cancer.
Hartmann, TN; Burger, M; Burger, JA;
J Biol Regul Homeost Agents. 2004; 18(2):126-130
Biomarkers in non-small cell lung cancer prevention.
Hilbe, W; Dirnhofer, S; Greil, R; Wöll, E;
Eur J Cancer Prev. 2004; 13(5):425-436
Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells.
Burger, M; Glodek, A; Hartmann, T; Schmitt-Gräff, A; Silberstein, LE; Fujii, N; Kipps, TJ; Burger, JA;
Oncogene. 2003; 22(50):8093-8101
Originalarbeiten (Zeitschrift)
Disturbance in the serum IgG subclass distribution in patients with anti-Hu positive paraneoplastic neurological syndromes.
Blaes, F; Klotz, M; Funke, D; Strittmatter, M; Kraus, J; Kaps, M;
Eur J Neurol. 2002; 9(4): 369-372.
Originalarbeiten (Zeitschrift)
How successful are oncologists in identifying patient distress, perceived social support, and need for psychosocial counselling?
Söllner, W; DeVries, A; Steixner, E; Lukas, P; Sprinzl, G; Rumpold, G; Maislinger, S;
Br J Cancer. 2001; 84(2):179-185
Originalarbeiten (Zeitschrift)
Non-small-cell lung cancer: dose escalation by target splitting with asymmetric collimation.
Wurstbauer, K; Deutschmann, H; Sedlmayer, F; Kogelnik, HD;
Clin Lung Cancer. 2001; 3(2): 151-153.
Originalarbeiten (Zeitschrift)
Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung Cancer.
Krajnik, G; Mohn-Staudner, A; Thaler, J; Greil, R; Schmeikal, S; Marhold, F; Deutsch, J; Preiss, P; Malayeri, R; Schäfer-Prokop, C; Wein, W; Huber, H; Pirker, R;
Ann Oncol. 2000; 11(8): 993-998.
Originalarbeiten (Zeitschrift)
Costs of standard and conformal photon radiotherapy in Austria.
Hohenberg, G; Sedlmayer, F;
Strahlenther Onkol. 1999; 175 Suppl 2: 99-101.
Originalarbeiten (Zeitschrift)
Radiotherapy for lung cancer: target splitting by asymmetric collimation enables reduction of radiation doses to normal tissues and dose escalation.
Wurstbauer, K; Deutschmann, H; Kranzinger, M; Merz, F; Rahim, H; Sedlmayer, F; Kogelnik, HD;
Int J Radiat Oncol Biol Phys. 1999; 44(2): 333-341.
Originalarbeiten (Zeitschrift)
Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial.
Krajnik, G; Wein, W; Greil, R; Marhold, F; Mohn-Staudner, A; Kummer, F; Malayeri, R; Zöchbauer-Müller, S; Huber, H; Pirker, R;
Eur J Cancer. 1998; 34(12): 1977-1980.
Originalarbeiten (Zeitschrift)
Complete spontaneous remission in a patient with metastatic non-small-cell lung cancer. Case report, review of the literature, and discussion of possible biological pathways involved.
Kappauf, H; Gallmeier, WM; Wünsch, PH; Mittelmeier, HO; Birkmann, J; Büschel, G; Kaiser, G; Kraus, J;
Ann Oncol. 1997; 8(10): 1031-1039.
Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial.
Prior, C; Oroszy, S; Oberaigner, W; Schenk, E; Kummer, F; Aigner, K; Hausmaninger, H; Peschel, C; Huber, H;
Eur Respir J. 1997; 10(2): 392-396.
Originalarbeiten (Zeitschrift)
Peripheral blood lymphocyte subsets and survival in small-cell lung cancer.
Chest. 1994; 105(6):1673-1678
Originalarbeiten (Zeitschrift)
The role of iodine-123-Tyr-3-octreotide scintigraphy in the staging of small-cell lung cancer.
J Nucl Med. 1993; 34(9):1397-1402
Originalarbeiten (Zeitschrift)